Dyanne Trial Targets Early Alzheimer's Prevention
D
David Perlmutter during a brain health panel discussion
Mental HealthMedicalTesting
Story of claim
The Dyanne trial focuses on preventing dominantly inherited Alzheimer's by starting drug therapy before amyloid deposition. It uses genetic diagnosis to target those at high risk.
- Goal: Conduct a primary prevention trial for genetically defined Alzheimer's using early drug intervention.
- Proof: The trial uses genomic definitions to implement early drug therapy, potentially delaying or preventing disease onset.
- Nuances:
- 75% penetrance indicates high likelihood of developing dementia
- $88 million grant from the National Institute of Aging
- Impact on Life: Could potentially delay the onset of Alzheimer's symptoms, improving quality and expectancy of life for at-risk individuals.
Investments
- Price: Funded by an $88 million grant
- Time: 5-year initial phase with ongoing research
- Effort: Requires comprehensive genetic screening and trial participation
Risks
Participation is limited to genetically predisposed individuals; potential side effects of experimental drugs.
Alternatives
- Lifestyle changes such as exercise and diet may delay symptom onset
- Other clinical trials targeting early stages of Alzheimer's
Get Started 🚀
- Seek genetic counseling if you have a family history of Alzheimer's
- Inquire about enrolling in the Dyanne trial or similar studies
- Stay informed on trial developments and new findings
Brogevity AI can make mistakes. Check important info.